NCT04356664CompletedPhase 4
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis: Randomised Prospective Study.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Jul 2025
Brief summary (registry, in English)
To assess the impact of the administration of a long-acting GnRH agonist prior to frozen embryo transfer (FET) on clinical pregnancy rates within an assisted reproductive technology (ART) protocol, in patients with endometriosis and/or adenomyosis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (actual)
- First submitted
- 17 Oct 2024
- Start date
- 15 Nov 2024
- Lead sponsor
- Hospital Foch
- Diseases
- Endometriosis
- NCT number
- NCT04356664
- EU CT number
- 2024-519126-20-00
- EudraCT number
- 2019-003645-16
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 180
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of implantation failures (≥2)
- Known hypersensitivity to GnRH, GnRH analogues, or any excipients in DECAPEPTYL® LP, 11.25 mg
- Known hypersensitivity to estradiol/progesterone/acetylsalicylic acid/folic acid/cefixime/levofloxacin
- Known or suspected breast cancer, or history of breast cancer
- Known or suspected cancer of the reproductive system, or history of reproductive system cancer
- Known or suspected estrogen-dependent malignant tumors
Other
- BMI > 35
- Pregnancy and breast
- Endometrial abnormalities
- Known uni or bilateral hydrosalpinx
Who the study is looking for
- Women aged 18 to 36 with endometriosis and/or adenomyosis
- Having undergone IVF/ICSI with freeze-all, and for whom a blastocyst FET is planned
- A normal uterine cavity
- An MRI with contrast injection confirming endometriosis and/or adenomyosis during the inclusion visit (MRI performed after patient selection if no results from the past 6 months are available or interpretable)
- Having signed a consent form
- Affiliated with a health insurance plan
Age in the registry: 18 years to 64 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Foch Coordinator of this site? Confirm its status | Suresnes | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.